Novo Nordisk updates DKK 15B buyback progress
Novo Nordisk A/S is executing a large share repurchase programme of up to DKK 15 billion over 12 months beginning 4 February 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Novo Nordisk A/S is executing a large share repurchase programme of up to DKK 15 billion over 12 months beginning 4 February 2026. Within this, it plans to buy back B shares for up to DKK 3.8 billion from 4 February to 4 May 2026.
As of 6 February 2026, Novo Nordisk has repurchased 750,000 B shares at an average price of DKK 296.40, with a total value of DKK 222,297,903. Incentive plan activity led to a net transfer out of 3,841,954 B shares. The company now holds 18,283,326 B shares as treasury shares, equal to 0.4% of its 4,465,000,000 total A and B shares.
Insights
Large DKK 15B buyback is underway, but early days and dilution from incentives offsets some impact.
Novo Nordisk outlines a substantial share repurchase programme of up to DKK 15 billion over 12 months starting 4 February 2026, with a first tranche of up to DKK 3.8 billion through 4 May 2026. Early activity shows steady daily repurchases.
By 6 February 2026, the company had bought 750,000 B shares for DKK 222,297,903 at an average price of DKK 296.40. Over the same short period, incentive programmes caused a net transfer of 3,841,954 B shares out of the company, which partially offsets the effect of repurchases.
After these transactions, Novo Nordisk holds 18,283,326 B shares as treasury shares, corresponding to 0.4% of its 4,465,000,000 total A and B shares. Future disclosures on progress toward the planned DKK 15 billion over the 12‑month period will show how aggressively the company continues buying.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is the size and timing of Novo Nordisk’s initial 2026 buyback tranche?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
February 9, 2026
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 9 February 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.
Under the programme initiated 4 February 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period from 4 February 2026 to 4 May 2026.
Since the announcement of the programme, the following transactions have been made:
Number of B shares |
Average purchase price |
Transaction value, DKK | |
| 4 February 2026 | 270,000 | 302.71 | 81,730,658 |
| 5 February 2026 | 280,000 | 291.98 | 81,754,584 |
| 6 February 2026 | 200,000 | 294.06 | 58,812,661 |
| Accumulated under the programme | 750,000 | 222,297,903 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
Transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 3,841,954 B shares in the period from 4 February 2026 to 6 February 2026. The shares in these transactions were not part of the Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of 18,283,326 B shares of DKK
0.10 as treasury shares, corresponding to 0.4% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 6 February 2026, Novo Nordisk has since 4 February 2026 repurchased a total 750,000 B shares at an average share price of DKK 296.40 per B share equal to a transaction value of DKK 222,297,903.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
| Ambre James-Brown | Liz Skrbkova (US) |
| +45 3079 9289 | +1 609 917 0632 |
| globalmedia@novonordisk.com | lzsk@novonordisk.com |
| Investors: | |
| Michael Novod | Jacob Martin Wiborg Rode |
| +45 3075 6050 | +45 3075 5956 |
| nvno@novonordisk.com | jrde@novonordisk.com |
| Max Ung | Sina Meyer |
| +45 3077 6414 | +45 3079 6656 |
| mxun@novonordisk.com | azey@novonordisk.com |
| Alex Bruce | Christoffer Sho Togo Tullin |
| +45 34 44 26 13 | +45 3079 1471 |
| axeu@novonordisk.com | cftu@novonordisk.com |
| Frederik Taylor Pitter | |
| +1 609 613 0568 | |
| fptr@novonordisk.com |
Company announcement No 08 / 2026
Novo Nordisk A/S Investor Relations | Novo Alle 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
| Company announcement No 8 / 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: February 9, 2026 |
NOVO NORDISK A/S
Maziar Mike Doustdar Chief Executive Officer |